What Does Relative Dose Intensity Mean?

Relative dose intensity, often written RDI, is the percentage of your planned chemotherapy that you actually received in the time it was meant to take.¹ It counts the doses you got and also how closely they kept to schedule, so a delay can lower it as much as a smaller dose can. Doctors watch it because, for many common cancers, receiving close to the full planned treatment goes with better long-term results.² It is a guide rather than a grade, though, and a lower figure is sometimes the result of a deliberate and sensible choice.

How Relative Dose Intensity Is Calculated

RDI compares two rates of drug delivery. Planned dose intensity is the amount of drug your treatment plan intends you to receive over a set time, such as per week. Actual dose intensity is the amount you really received over that same time. RDI is the actual figure divided by the planned figure, given as a percentage.³ A result of 100% means everything arrived on time, and 80% means you got four-fifths of the planned drug per week.

Take a plan of 100 mg every 2 weeks for 12 weeks, which totals 600 mg. If every dose is cut by 20% and nothing is delayed, RDI is 80%. If you get full doses but the course stretches to 15 weeks, RDI also comes out at about 80%.

Time matters, not just the total, because chemotherapy is spaced so cancer cells cannot recover between doses. Finishing the full total late still counts as lower intensity, which is why even a one-week delay shows up in your RDI. A team looking at a lower number usually has to check the treatment record to see whether each dose was smaller or the same drug was spread over more weeks.

RDI can be worked out separately for each drug and also for the combined treatment.⁴ That matters because in a combination, one drug might be given in full while another is reduced.

The planned figure comes from the standard schedule for your regimen, not from a target your team invented for you. If your team deliberately changed the plan before you started, for example to a gentler version, RDI may be calculated against either the original or the adjusted plan. If a number seems odd, it is fair to ask which plan it was compared with.

RDI is sometimes written as a decimal, such as 0.85, which means 85%. You can ask your oncologist what your RDI is so far and what they aim for.

What a Lower RDI Means for Your Treatment

Many teams treat 85% or more as the goal.⁵ The reason is that after colon cancer surgery, risk of death stayed flat above 85% but rose steadily below it.⁶ Dropping from 85% to 75% raised the risk of death by about a fifth, yet going from 85% up to 95% did not lower the risk any further.⁷

The same pattern shows up across several cancers. In advanced ovarian, lung, and breast cancers treated with carboplatin-based regimens, an RDI below 80 to 85% carried about 17% higher risk of death.⁸ In advanced bowel and pancreatic cancers on FOLFOX-type regimens, the increase was about 39%.⁹ In early breast cancer, an RDI under 85% was strongly linked to the cancer returning.¹⁰ And in older people with advanced lung cancer, those on full doses lived a median 18 months compared with 7 months for those needing reductions.¹¹

These risk figures need careful reading. A 17% higher risk is a relative increase that compares two groups. It is not a 17% chance of dying, and it does not give your personal chance of anything. How much it matters in absolute terms depends on how high the risk was to begin with, which varies a lot between cancers and stages.

Some of the link also reflects how sick people were. People who need reductions are often sicker to begin with, which affects survival on its own. A lower RDI is a warning sign worth discussing, not proof that your treatment has failed.

Most of the evidence comes from treatment meant to cure or to lengthen life, such as after surgery or in early cancers. There, missing part of the plan may leave behind cancer cells that would have been killed. In treatment aimed at control, teams weigh symptoms and quality of life more heavily against dose, so the same number may be read differently.

One low reading is also different from a pattern. RDI is usually summed across the whole course, so one delayed cycle early on can be a small part of the total or be offset later. A team becomes more concerned when delays keep happening cycle after cycle and the running figure drifts toward the 85% line. Asking for the running RDI, not just the latest cycle, gives a fairer picture.

Why Doses Get Delayed or Reduced

A low count of the white cells that fight infection is the main reason doses get held or cut.¹² In one study, about 30% of people had at least one dose delayed and 20% had a dose reduced because of it.¹³ Another 8% ended up in hospital with febrile neutropenia, which means a fever while white cells are low.¹⁴ RDI averaged 81% in people with these problems compared with 92% in those without.¹⁵

Low white cells usually cause no symptoms by themselves, which is why blood tests, not how you feel, decide whether to go ahead. Your blood is checked before each cycle. If the count is too low, the team may wait a week. Giving more chemotherapy while the count is low raises the risk of a serious infection because the bone marrow has not recovered. Waiting is a safety step, and for most people the count recovers and treatment resumes. That week of delay does lower your RDI.

Other side effects can also hold a dose. Nerve damage, such as numb or tingling fingers and feet, can worsen if treatment continues. Mouth sores, severe diarrhea, and liver or kidney test changes are other common reasons. Which side effect is the limit depends on the drugs in your regimen, so your team can tell you what to watch for.

Some people are at higher risk of a lower RDI. Older age, obesity, and fever with low white cells are all linked to it.¹⁶ In older women with breast cancer, only 63% reached 85% or more, with age 70 and over and other health conditions linked to lower RDI.¹⁷ Yet in people aged 70 and over getting near-full doses, age by itself did not raise the risk of blood-count problems.¹⁸ Fitness and other illnesses often matter more than age alone. If a cut is proposed, ask whether it is based on your health or your age.

Heart, kidney, or liver problems can change how safely your body handles a drug, so the dose may be adjusted from the start. If your starting dose was set lower than standard, ask whether the plan is to raise it if you tolerate the first cycles.

How to Keep Your Dose Intensity Up

G-CSF shots, such as filgrastim or pegfilgrastim, help your body make white cells faster.¹⁹ In breast cancer, people given G-CSF from the start were about 40% less likely to fall below 85% in the first cycle.²⁰ Keeping dose intensity up with these shots is considered good value as well as effective.²¹

Getting one usually means a shot under the skin the day after chemo, or an on-body patch. Bone aches are a common side effect. Boosters are most often given with regimens known to cause a high chance of low white cells, or to people with other risk factors such as older age. They are not routine for every chemotherapy, because many regimens rarely drop white cells enough to need them. If your regimen is lower risk, the team may hold them back and use them only if a problem occurs. It is reasonable to ask whether your regimen carries a high risk of low white cells.

Boosters have limits. They help white cells recover but do not prevent nausea, mouth sores, nerve damage, or other side effects that also force delays, so your team may still need to lower a dose for those. They are also given at a set time after chemotherapy, not before, and getting that timing wrong can reduce their usefulness.

Reporting symptoms early helps too. With app-based symptom reporting in breast cancer, 86% reached at least 85% RDI, compared with 67% with usual care.²² In a large trial of people on chemo pills, nurse-led remote monitoring raised RDI from 89% to 93%.²³ Telling your team quickly about diarrhea, mouth sores, or fever lets them treat problems before a dose has to be skipped.

In practice, that means checking in as instructed on the things your team named: temperature, how much you can eat and drink, bowel changes, and mouth soreness. Call the same day for a fever or if you cannot keep fluids down, rather than waiting for the next appointment. A few habits protect the schedule as well: take your temperature as advised, use anti-sickness medicines as prescribed, and keep the blood test appointments before each cycle.

When a Lower Dose Is the Right Choice

In treatment aimed at control rather than cure, lower doses are sometimes needed because people are sicker and at higher risk of serious side effects.²⁴ In one modeled example with prostate cancer, a lower dose caused fewer side effects and fewer interruptions, so less drug was actually missed.²⁵ If full doses repeatedly cause problems that interrupt treatment, the drug delivered over months can be less than with a slightly lower, steadier dose. A reduction made early and kept stable is sometimes better than repeated stops and restarts. That is a judgement made for each person, not a rule that lower is better.

When the goal is cure, a team tends to accept more side effects to protect dose. When it is control, a lower dose you tolerate may be the better path. If a reduction is proposed, ask whether the goal is cure or control, what side effect the reduction prevents, and whether the dose can be raised again later.

Dose caps for larger bodies can also lower RDI. Chemotherapy doses are usually based on an estimate of body size from height and weight. But some hospitals cap that estimate at 2.0 square metres, and in one study larger people received a median RDI of 84% compared with 93%.²⁶ Caps exist partly out of concern about toxicity in larger people, though the evidence on whether they are needed is debated. Not every hospital caps, and not every drug is capped. If you are larger, you can ask whether your dose is capped and why.

RDI for Chemo Pills and Newer Drugs

RDI was designed for drugs given by drip but is now also used for cancer pills.²⁷ It is used, for example, for kidney cancer treatment combining immunotherapy with targeted pills.²⁸ With pills, RDI also reflects doses forgotten or skipped at home. In one clinic, average RDI on pills was 94% at 6 months, but 43% of people had reductions, and taking doses consistently slipped after 6 months.²⁹

Pills are usually taken daily for set weeks, so RDI reflects both the tablets you take and any days or weeks your team tells you to pause. Many pill regimens have planned breaks, and those should not count as shortfalls, so the number depends on what the plan was.

People skip or cut pills for understandable reasons. Tiredness, nausea, rash, or sore hands and feet can make it tempting to skip doses without saying anything. Cost, difficulty getting refills, and forgetting when routines change are other common reasons. Because nobody sees a skipped pill, the team may read a falling response as the drug failing when it is the dose that lapsed.

To stay on track, use a pill box or phone reminder, and never stop or halve doses without telling your team. Report side effects rather than quietly skipping, and bring leftover pills to appointments if asked.

A reduction ordered by your team is a planned change that often keeps you on treatment longer, and it is different from missing doses. Many people on pills need at least one reduction, and that is common rather than a sign of failure. Ask whether a reduced dose is expected to work as well for your drug, since this differs between treatments.